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Summary
Aim: Sono-lysis is a new therapeutic procedure for arterial recanalization. The aim of the study
was to conﬁrm the safety and efﬁcacy of intravascular sono-lysis using EKOS system with 3F
microcatheter EkoSonic and 2.05—2.35MHz ultrasound frequencies.
Methods: Nine patients admitted to the stroke unit with acute middle cerebral artery (MCA) or
basilar artery (BA) occlusion were enrolled to the study. Treatment using EKOS system started
within 8 h after stroke onset. Neurological deﬁcit on admission (using NIHSS), after 24 h and
after 7 days, MCA/BA recanalization at the end of intervention, occurrence of symptomatic
intracerebral hemorrhage (SICH), and 3-month clinical outcome (using Modiﬁed Rankin score —
mRS) were evaluated.
Results: Nine patients were included in the pilot study (6 males, 3 females; age 51—80, mean
65± 10.4 years) with NIHSS 10—33 (median 19.0) points on admission. Five patients suffered
from MCA occlusion, 4 patients from BA occlusion. Complete/partial recanalization at the end
of EKOS treatment was achieved in 3 (33%)/4 (44%) patients, resp. Median NIHSS values at
the end of EKOS treatment/24 h/7 days after stroke onset were 17.0/12.0/6.0 points, resp. No
SICH was detected on control computed tomography. Four (44%) patients were independent at
3months (mRS 0—3); median mRS was 4.
Conclusions: According to the results of the presented pilot study, EKOS system seems to be a
new treatment option for acute stroke patients.
© 2012 Elsevier GmbH.
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ntroduction
troke is one of the most frequent causes of mortality, mor-
idity and disability of population in developed countries
1,2]. Ischemic stroke (IS) is the most common type of stroke
hich constitutes about 80% of all strokes.
The most often cause of IS is an acute occlusion of cere-
ral arteries which can be demonstrated in more than 70% of
atients in the ﬁrst 3—6 h after onset of symptoms [3]. Very
igh mortality during the ﬁrst month, which ranges between
0% and 17% and even up to 75% in patients with expan-
ive ischemia, documents the importance of IS [4]. Finally,
nly about 30% of IS patients are independent after 3months
2].
The independent prognostic factors of IS are not only
omorbidities and complications but especially location
f cerebral artery occlusion and time to recanalization.
arly recanalization [within 6 h after onset of symptoms]
s associated with a signiﬁcantly higher chance of self-
ufﬁciency after 90 days with a signiﬁcant reduction of
ortality [5]. In the last decade, the number of meth-
ds using to acceleration of artery recanalization strongly
ncreased. In addition to pharmacological methods, espe-
ially intravenous (IVT) and intra-arterial thrombolysis (IAT)
6—8], mechanical (neuro-interventional) methods (i.e. per-
utaneous transluminal angioplasty with stenting, Merci
etriever®, Penumbra®, Solitaire® stent, sono-lysis, EKOS®,
PAR®, LATIS®, Amplaplatz Goose-Neck Snare®, Attractor-
8® or Neuronet® were tested and introduced into clinical
ractice similarly as in the treatment of heart ischemic syn-
romes [9—13].
Data from the meta-analysis of 53 clinical trials (including
066 patients) suggests that early recanalization is present
nly in 24.1% patients without speciﬁc treatment (spon-
aneous recanalization), 46.2% patients treated with IVT,
3.2% patients treated with IAT, 67.5% of patients treated
ith combined IVT—IAT and in up to 83.6% patients treated
ith mechanical methods [5]. Nevertheless, the use of these
ethods only in specialized centers represents the main
imitation.
Sono-lysis is one of the methods used for the acceleration
f recanalization of the occluded intracranial artery.
echanisms of the effects of sono-lysis
lthough the complex effect of ultrasound on the accel-
ration of thrombus lysis is not yet fully understood, it is
ssumed that the ultrasonic waves accelerate enzymatic ﬁb-
inolysis by primarily non-thermal mechanisms — increasing
he transport of ﬁbrinolytic agents into the thrombus by
echanical disruption of its structure [14], direct activa-
ion of ﬁbrinolytic enzymes, either mechanical breaking of
he complex molecules, in which ﬁbrinolytic enzymes are
nactivated by binding to their inhibitors, or irritation of
he endothelium with increased production of ﬁbrinolytic
nzymes [15,16], transient peripheral (capillary) vasodilata-
ion caused probably by increased production of nitrite oxide
n the endothelium [17,18]. Radiation force and acoustic
avitation are the next possible and discussed mechanical
ffects of ultrasound [19].
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n vitro and in vivo studies
ifferent frequencies (20 kHz to 3.4MHz) and intensities of
ltrasound with different effects have been used in vari-
us in vitro studies [20,21]. Low frequency (about 20 kHz)
nd high intensity ultrasound lead to a rapid and efﬁ-
ient lysis of thrombi into microscopic fragments primarily
y direct mechanical effect although the signs of activa-
ion of ﬁbrinolytic lysis were also observed. These studies
ven demonstrated the ability of ultrasound to disrupt both
brous and calciﬁed atherosclerotic plaques [15,22—26].
nfortunately thermal impairment and perforation of vas-
ular walls were observed as side effects.
Unlike low-frequency ultrasonic waves, the high fre-
uency ultrasound (0.5—3.4MHz) with ultrasound intensities
igher than 1W/cm2 led primarily to the increase of
brinolytic-induced ﬁbrinolysis [27—32]. Sono-lysis in these
tudies accelerated lysis of thrombus in the presence of a ﬁb-
inolytic. Without the presence of ﬁbrinolytics, neither lysis
or mechanical thrombus fragmentation were observed.
Similar results were found also in in vivo studies with
nimal models [25,26,33,34]. Sono-lysis using ultrasound
ith low frequencies and high intensities in dog models
f femoral and coronary artery resulted to recanalization
f thrombosis without the use of ﬁbrinolytic agents. How-
ver, histological signs of damage to the vascular wall were
ound in some models. Sono-lysis effect was demonstrated
n studies in combination with a systemic administration of
hrombolytics (recombinant tissue plasminogen activator —
t-PA, urokinase, streptokinase) [35,36]. Ishibashi et al. [37]
tudied the effect of high-frequency ultrasound with a fre-
uency of 490 kHz and low-intensity (0.13W/cm2) in a rabbit
emoral thrombosis model to test the combined application
f ultrasound-lysis with monteplase. Percentage of recanal-
zation in combination therapy has increased from 16.7 to
6.7%.
linical studies in patients with acute IS
LOTBUST trial (Combined Lysis of Thrombus in Brain
schemia using transcranial Ultrasound and Systemic TPA)
as the ﬁrst randomized study testing the therapeutic effect
f ultrasound (sono-lysis) in patients with acute IS [38].
n this study, all patients with acute MCA occlusion were
reated with IVT. Patients were randomized to the sono-
ysis group with additional therapeutic transcranial Doppler
nsonation with 2MHz probe for 2 h, and control group. In
ono-lysis group, there was a threefold higher chance for a
omplete recanalization of the occluded arteries than in the
ontrol (rt-PA only) group without the increase of the risk of
ymptomatic intracerebral hemorrhage (SICH).
Similar results were published by Eggers et al. [39],
ho used sono-lysis (transcranial duplex probe with a fre-
uency of 1.8—4MHz) in IVT treated patients. A higher rate
f complete recanalization and better early outcome and
linical status after 3months (mRS 0—1: 21% vs. 0%) were
chieved in the treatment group than in control group.
owever, a higher incidence of SICH (15.7% vs. 5.6%) in
atients receiving sono-lysis was observed. In a multicenter
ase—control Thrombotripsy study, the sono-lysis in patients
ith acute MCA occlusion was performed using transcranial
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pEndovascular sono-lysis using EKOS system
2MHz duplex probe [40]. Length of insonation was maxi-
mum of 45min. Percentage of arterial recanalization was
signiﬁcantly higher in the sono-lysis group compared to the
control group (69% vs. 8% at 6 h after onset of symptoms),
as well as a good clinical outcome after 90 days (mRS 0—2:
61.5% vs. 32.7%). Sono-lysis effect was more evident in the
group of patients contraindicated to IVT than in IVT treated
patients. Percentage of SICH was similar in the treated and
control groups (3.8%).
The effect of sono-lysis in IS patients contraindicated to
IVT was also described by other authors [41,42]. Eggers et al.
[41] published a set of patients with acute IS and MCA occlu-
sion treated with sono-lysis using 2MHz duplex transcranial
probe. They detected higher number of at least partial arte-
rial recanalization and National Institutes of Health Stroke
Scale (NIHSS) improvement of more than 4 points in the
treated group.
In the next study, patients with acute MCA occlusion
were randomized into three treatment groups — 20 patients
were treated with IVT within 3 h since stroke onset, 10
patients received IAT and 10 patients were treated by 60-min
sono-lysis using 2MHz transcranial duplex probe in the 6-h
time window. The study demonstrated superior efﬁcacy and
safety of sono-lysis when compared to the IVT [43]. During
the ﬁrst 24 h, a clinical improvement was observed in only
45% of patients treated with IVT, but in up to 70% of patients
treated with sono-lysis or IAT. The incidence of SICH was 5%
in the IVT group, 0% in the sono-lysis group and 20% in the
IAT group.
In later sono-lysis studies, the additive effect of echocon-
trast agents has been tested. The ﬁrst study with Levovist®
(galactose based air microbubbles, Schering, Germany) and
Sonovue® (sulphurhexaﬂuoride microbubbles, Bracco, Italy)
demonstrated an increase in the percentage of arterial
recanalization and better clinical improvement in acute
IS patients treated with sono-lysis in combination with
echocontrast agent [44]. This study demonstrated also the
safety of echocontrast agent use. SICH occurred in 3.3% in
the Levovist® group and in 2.1% in the Sonovue® group.
Better improvement of neurological symptoms as well as
the improvement of the ﬂow signal in the occluded arteries
were showed in the study of Perren et al., using sono-lysis
with 2MHz transcranial duplex probe in combination with
Sonovue® in patients with acute MCA occlusion treated with
IVT [45].
The pilot randomized clinical trial with the new gen-
eration echocontrast agent (perﬂuten-lipid microspheres)
demonstrated additive effect of echocontrast agent in
patients treated with IVT and sono-lysis [46]. Percentage of
complete recanalization within 2 h after therapy start was
50% in the group treated with a combination of IVT, sono-lysis
and echocontrast agent in comparison with 18% in the con-
trol group selected from the CLOTBUST study. Asymptomatic
intracerebral hemorrhage was found in 25% of patients in the
treatment group and in 33% in the control group. A higher
percentage of asymptomatic hemorrhagic transformation
was also associated with a higher percentage of recanal-
ization and better clinical status outcome in this study. No
SICH was detected. Similar results with higher recanaliza-
tion rate, higher percentage of good clinical outcome and
also higher number of asymptomatic hemorrhagic transfor-
mation were found by Dinia et al., who used the combination
C
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f IVT, sono-lysis and administration of echocontrast agent
47]. This result supported the hypothesis that the ﬁnding
f asymptomatic hemorrhagic transformation of ischemic
esion is a marker of early reperfusion and it is associated
ith a higher chance of good clinical outcome.
These promising results were tested in the TUCSON
Transcranial Ultrasound in Clinical Sonothrombolysis) study.
ono-lysis using 2MHz transcranial Doppler probe in combi-
ation with an echocontrast agent MRX-801 (perﬂuten-lipid
icrospheres, ImaRx Therapeutics, Inc., USA) as adjunctive
herapy to IVT was used [48]. Although the study showed
hat administration of a dose of 1.4ml of MRX-801® in 90-min
ontinuous infusion during the IVT combined with sono-lysis
s safe, the study was discontinued due to the higher SICH
isk in higher dose of echocontrast agent.
Explanation of the effect of sono-lysis in the humans
equired several studies. The authors demonstrated a direct
ffect of sono-lysis on the ﬁbrinolytic system in both healthy
olunteers and IS patients using transcranial 2MHz duplex
robe [15,16,49]. In healthy volunteers, 1-h sono-lysis of
CA or radial artery led to the decrease of ﬁbrinolysis
nhibitors (PAI-1 antigen, plasminogen activity and alpha-2
ntiplasmin) levels [16,49]. Similar results were obtained in
atients with acute IS. Also t-PA antigen was increased in
ono-lysis group in comparison with a control group. These
ndings were more evident in patients treated with IVT in
ombination with sono-lysis than in sono-lysis group only.
here were no signiﬁcant differences in the number of SICH
etween the groups. This study demonstrated that acti-
ation of the ﬁbrinolytic system is one of the therapeutic
ffects of ultrasound.
On the contrary to the studies with diagnostic frequen-
ies, studies with lower frequency (300 kHz) ultrasound
ed to the increased risk of intracranial bleeding and
lood—brain barrier breakdown.
TRUMBI (TRanscranial low-frequency Ultrasound
ediated thrombolysis in Brain Ischemia) study used
ow-frequency ultrasound (300 kHz, the intensity of
00mW/cm2) for 90min for sono-lysis in patients with
cute cerebral artery occlusion treated with IVT. The study
as early terminated due to the extreme increase in the
isk of SICH and of subarachnoid hemorrhage [50]. One of
he hypotheses explains the increased risk of bleeding in
he study by the abnormal permeability of the blood—brain
arrier in humans caused by low frequency ultrasound.
ultiple reﬂecting and focusing of ultrasonic waves within
he skull, which can signiﬁcantly increase the intensity of
ltrasound applied in some areas of the brain, represent
nother option. The increased risk could also contributed
o the excessive activation of the endogenous ﬁbrinolytic
ystem in combination with IVT.
Reinhard et al. [51] demonstrated that 60-min sono-
ysis using an ultrasound frequency of 300 kHz leads to the
ncreased permeability of the blood—brain barrier. The study
as also prematurely terminated after the inclusion of 4
atients.linical studies with endovascular sono-lysis
KOS system® is the ﬁrst system that allows the appli-
ation of endovascular ultrasound-lysis, using a catheter
68 M. Kuliha et al.
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tigure 1 Occlusion of middle cerebral artery detected by co
aphy (b).
or intra-arterial administration of drugs (e.g. thrombolyt-
cs) terminated with the emitter of ultrasonic waves. It
mits ultrasound waves with the frequency between 1.7 and
.35MHz and with the emitted intensity of 400mW/cm2 into
he thrombus. The ﬁrst clinical studies with endovascular
ono-lysis were used for the coronary arteries. In the ACUTE
Analysis of Coronary Ultrasound Thrombolysis Endpoints
n Acute Myocardial Infarction) study, the low-frequency
45 kHz) ultrasound with a high intensity (18W/cm2) was
sed in acute coronary artery occlusion [52]. Complete
ecanalization was achieved in 87% patients. No side effects
ere observed during the therapy and 80% of patients
howed clinical improvement.
Other studies showed the effect of endovascular
ltrasound-lysis by EKOS system in patients with deep venous
hrombosis of lower extremities and in patients with pul-
onary embolism [53—56].
Mahon et al. [57] published the ﬁrst experience with
ndovascular sono-lysis using the EKOS system in patients
ith acute IS. They used a combination of IAT using rt-
A with endovascular ultrasound applied continuously for
0min in 10 patients with MCA occlusion and in 4 patients
ith BA occlusion. Partial or complete recanalization was
etected in 57% patients and there were no adverse effects
bserved during the therapy.
The authors also performed a prospective mono-centric
tudy aimed to conﬁrm a safety and efﬁcacy of intravas-
ular sono-lysis using EKOS system® with 3F microcatheter
koSonic and 2.05—2.35MHz ultrasound frequencies for the
ecanalization of brain arteries in acute stroke patients
ithin an 8-h time window.
aterial and methods
he pilot, prospective, observational, single center study
f consecutive patients presenting with acute stroke symp-
oms and radiologically conﬁrmed MCA or BA occlusion
as performed. The entire study was conducted in accor-
ance with the Helsinki Declaration of 1975 (as revised in
983, 2004 and 2008). It was approved by the Local Ethics
w
m
v
aed tomography angiography (a) and digital subtraction angiog-
ommittee of University Hospital Ostrava. All subjects
igned informed consent. In case of technical problems with
egard to signing, their signature was also veriﬁed by an
ndependent witness.
Patients with (1) acute IS, (2) NIHSS score of 10—24 points
n admission, (3) MCA or BA occlusion detected by computed
omography (CT) angiography and digital subtraction angiog-
aphy (DSA) (Fig. 1a and b), (4) admitted and treated within
h since stroke onset, and with (5) signed informed consent
ere consecutively enrolled to the study during 12months.
Exclusion criteria were (1) previous disability, (2)
ntracranial bleeding or tumor on brain CT, (3) infarction
n brain CT in more than 2/3 of the MCA territory, and (4)
artial or complete recanalization of brain artery after IVT
reatment detected using transcranial duplex sonography.
A physical examination, blood samples, electrocardio-
ram, chest X-ray, and standard neurologic evaluation by
certiﬁed neurologist using the NIHSS were performed on
dmission followed by brain CT and CT angiography (CTA) of
ervical and intracranial arteries. Patients underwent stan-
ard treatment [58,59]. Patients who fulﬁlled SITS-MOST
riteria [60] for IVT were treated using rt-PA intravenously
0.9mg/kg) within 4.5 h since stroke onset. Secondary pre-
entive therapy was administered according to the European
troke Organisation guidelines [59].
ndovascular sono-lysis using EKOS system
he interventional procedure started with arterial puncture
ia femoral approach. At the beginning of the proce-
ure, heparin was administered intraarterially (50 IU/kg).
hen, the 6F sheath insertion was performed with stan-
ard Seldinger technique. All patients underwent 4-vessel
iagnostic angiography with 4 or 5F pre-shaped catheters
nserted over the 0.035 in. diameter hydrophilic wires. The
F guiding catheter was introduced subsequently into the
arget brain supplying vessel over the same hydrophilic
ire and microcatheter with a support of a 0.014 in./300
icrowire was advanced behind the occluded intracranial
essel segment. Occlusion of MCA or BA was classiﬁed
ccording to the Thrombolysis in Cerebral Ischemie (TICI)
Endovascular sono-lysis using EKOS system 69
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criteria. The intraluminal position of the microcatheter
was always checked. All catheters were continuously
ﬂushed with heparinized saline. The microcatheter was then
replaced with the EKOS endovascular catheter terminated
with the emitter of ultrasonic waves and connected to the
central unit. The EndoWave System manufactured by EKOS
Corporation (Bothell, WA, USA) was used (Fig. 2a and b). It
consists of a 5.2F, 106 cm long infusion catheter, an ultra-
sound core wire, and a control unit with catheter interface
cables. The ultrasound wire delivers pulsed high frequency
(1.7—2.1MHz) and low-intensity (400mW/cm2) ultrasound
waves. Special care was taken for the location of a tip
of the catheter into the occluded segment of the artery
(Fig. 3). Both the insonation and the local administration of
tPA directly into the thrombus were simultaneously started.
In this study, a dose of 15mg/h of tPA was delivered by an
Figure 3 Insertion of the tip of the EKOS system catheter into
the occluded segment of the artery.
t
t
n
R
F
uS system.
nfusion pump with a maximal calculated total dosage not
xceeding 20mg of tPA.
Patients with partial recanalization after EKOS treatment
ere further treated by angioplasty and stent implantation.
adiological and clinical evaluation
he recanalization status at the end of DSA was evaluated
y blinded independent radiologist using the TICI criteria.
ICI IIc and III were evaluated as complete recanalization
Fig. 4), TICI IIa and IIb were evaluated as partial recanal-
zation.
Neurological and physical examinations were done before
herapy start and 24 h, 30 and 90 days after the start of
reatment. Certiﬁed neurologist performed evaluation of
eurological symptoms using NIHSS in all visits. Modiﬁed
ankin score was used for the evaluation of disability at days
igure 4 Complete recanalization at the end of sono-lysis
sing EKOS system.
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0 and 90. Good clinical outcome was deﬁned as a mRS 0—3,
oor clinical outcome as a mRS 4—6.
All adverse events were recorded. All changes in physi-
al examinations, worsening of neurological symptoms (>4
oints in NIHSS) and all disorders prolonging or requiring
ospitalization were recorded as adverse events.
Intracranial bleeds detected in the control brain CT
xamination 24 h after therapy onset were recorded.
ntracranial bleeding with worsening of neurological symp-
oms > 4 points in the NIHSS were evaluated as SICH (ECASS
criteria). Other intracranial bleeds were evaluated as
symptomatic intracranial hemorrhage (AICH).
In the control brain CT scan, detected brain edema asso-
iated with worsening of neurological symptoms > 4 points
n the NIHSS was evaluated as ‘‘symptomatic’’.
tatistical analysis
ata with a normal distribution was reported as
ean± standard deviation. All parameters not ﬁtting
o a normal distribution were presented as median and
ange. Statistical analyses were performed using SPSS 14.0
oftware (SPSS Inc., Chicago, IL, USA).
esults
ine patients (6 males, 3 females) were included in the pilot
tudy. The age range was 51—80, mean 65.0± 10.4 years.
IHSS on admission was 10—33 with median of 19.0 points.
ive patients suffered from MCA occlusion, 4 patients
orm BA occlusion. Mean time onset-to-treatment was
82± 184min.
Complete recanalization at the end of EKOS treatment
as achieved in 3 (33%) and partial in 4 (44%) patients,
esp. Mean time between diagnostic angiography and artery
ecanalization was 108.1± 39.9min. No SICH or symp-
omatic brain edema were detected on control CT.
Median NIHSS at the end of EKOS treatment was 17.0
oints. After 24 h, the median NIHSS was 12.0 and 7 days
fter stroke onset 6.0 points, resp. Four (44%) patients were
ndependent at 3months (mRS 0—3); median mRS was 4.
iscussion
he results of the pilot study demonstrated safety of
ndovascular sono-lysis using the EKOS system. SICH and also
alignant infarction were not detected in any patient.
Partial or complete recanalization of brain artery was
chieved in 77% patients in the presented study. In the simi-
ar study, Mahon et al. [57] achieved any recanalization only
n 57% patients treated by endovascular sono-lysis using the
KOS system.
Presented results are comparable with other studies
sing mechanical methods for brain artery recanalization.
n the MultiMerci study the partial or complete recanaliza-
ion was achieved in 55% patients with 9.8% occurrence of
ICH [61]. Higher recanalization rate was demonstrated in
he study with Penumbra system. Partial recanalization was
chieved in 54% patients and complete recanalization in
3% patients with 5.7% of periprocedural complications [62].
owever, the highest recanalization rates were achieved
sing the Solitaire stents. In the recent studies, partial orM. Kuliha et al.
omplete recanalization of brain artery was achieved in
8—90% patients with the occurrence of SICH of 2—17% and
ess than 8% of periprocedural complications [63—66].
Although the recanalization rate in published studies
sing new devices was quite high and still increasing, the
umber of independent patients did not exceed 60%. 44%
atients in the presented study were independent 90 days
fter stroke onset. In the previously mentioned studies,
1—59% patients were independent at day 90 with mRS 0—3
61—66].
Several limitations of the presented study should be men-
ioned. This was a single center observational pilot study.
he main goal was to assess the safety of endovascular
ono-lysis. Evaluation of artery recanalization is still very
ubjective even though the vascular status was evaluated
y blinded radiologist in the presented study.
In the future, the randomized multicenter study has to
e performed to conﬁrm a potential effect of endovascular
ono-lysis on the acceleration of artery recanalization.
onclusion
ono-lysis is a promising method of treatment of acute IS.
his is a relatively safe treatment with a high efﬁcacy in
he acceleration of cerebral arteries recanalization. A good
vailability and a low price are the advantages of transcra-
ial sono-lysis, but its use is limited by the quality of the
emporal bone window and the availability of an experi-
nced sonographer. Also endovascular sono-lysis seems to be
afe and effective. It is not dependent on the bone window
uality, but it is limited by the availability of interven-
ional radiologist. Further double-blind randomized studies
re needed to conﬁrm the safety and efﬁcacy of sono-lysis,
nd especially to determine the optimal frequency, intensity
nd character of the ultrasonic waves.
cknowledgements
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